liver cancer
Conditions
Interventions
Sponsors
Dongguan Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Stage IIb-IIIb hepatocellular carcinoma in accordance with the diagnosis and staging in accordance with the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) issued by the General Office of the National Health and Wellness Commission; 2) Liver function Child-Pugh classification A or B; 3) PS = 2 points; 4) Receiving systemic anti-tumor therapy (including (1) first-line therapy: atilizumab + bevacizumab sindilizumab + bevacizumab analog; donafenib lenvatinib sorafenib; FOLFOX4; and (2) second-line therapy: regorafenib apatinib karelizumab and tirilizumab); 5) assessed to be incapable of surgical and/or local treatment; and 6) aged 18 to 70 years; and 7) complete clinical data; and 8) Expected survival is greater than 3 months; 9) Good compliance.
Exclusion criteria
Exclusion criteria: 1) Those with chronic renal failure and severe respiratory failure; 2) those with combined severe cardiovascular and cerebrovascular diseases or active tuberculosis and other infectious diseases; 3) Those with active recurrent cancer; 4) those suffering from mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Alanine Aminotransferase;Aspartate aminotransferase;Total Bilirubin;Unconjugated bilirubin;Albumin;Alpha-fetoprotein;carcinoembryonic antigen;Carbohydrate Antigen 19-9;Interleukin-1;Interleukin-6;Interleukin-8;Interferon-?;Tumor Necrosis Factor-alpha;CD4+ T lymphocytes;CD8+ T lymphocyte;KPS score;Liver cancer-related Chinese medicine symptom scoring; | — |
Countries
China
Contacts
Public ContactJie Yun Xie
Dongguan Hospital of Traditional Chinese Medicine
Outcome results
None listed